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Abstract: Active commuting has the potential to decrease cardiovascular risk by increasing physical activ-
ity. We aimed to investigate the effects of active commuting to work for 12 months on body composition
and cardiovascular risk factors. Therefore, 73 hospital employees (age: 46 ± 9 years, 36% males), with a
predominantly passive way of commuting, were randomly assigned to an intervention group (IG) and a
control group (CG) in a 2:1 fashion. The IG was further divided into a public transportation plus active
commuting group (IG-PT) and a cycling group (IG-C). Both IGs were prompted to reach 150 min/wk
of moderate intensity exercise. Daily self-reported commuting details were verified by GPS tracking. All
subjects underwent assessment of body composition, resting blood pressure, glycemic control, and lipid
profile at the beginning and end of the study. Data for final analyses were available in 62 subjects. Com-
muting details indicated that the subjects randomized to IG changed their commuting habits. HbA1c
decreased by 0.2% [95%CI: -0.3, -0.2] in IG-PT but was not statistically different between groups (P
= .06). LDL cholesterol decreased in IG-C by 0.8 mmol/L [-1.1, -0.4] and by 0.6 mmol/L [-1.2, 0.1] in
IG-PT which can be considered biologically relevant but did not yield statistical significance. Body com-
position and blood pressure did not differ between groups. Active commuting to work for 12 months did
not change body composition but yielded relevant changes in lipid profile and glycemic control. Health
benefits of active commuting should be addressed by healthcare professionals when counseling individuals
that seek to improve their cardiovascular risk profile.
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1 |  INTRODUCTION
In developed countries, cardiovascular diseases (CVD) are 
the number one cause of death with a projected increase in 
prevalence,1 despite the fact that preventive strategies are well 
established and easily accessible.2 For the majority, the most 
effective CVD prevention strategy is to increase physical ac-
tivity (PA).3-5 Most international guidelines recommend that 
individuals accumulate at least 30 min/d, 5 d/wk of moderate 
intensity PA (ie, 150 min/wk in total)6,7 but the majority of 
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Active commuting has the potential to decrease cardiovascular risk by increasing 
physical activity. We aimed to investigate the effects of active commuting to work 
for 12 months on body composition and cardiovascular risk factors. Therefore, 73 
hospital employees (age: 46 ± 9 years, 36% males), with a predominantly passive 
way of commuting, were randomly assigned to an intervention group (IG) and a 
control group (CG) in a 2:1 fashion. The IG was further divided into a public trans-
portation plus active commuting group (IG-PT) and a cycling group (IG-C). Both 
IGs were prompted to reach 150 min/wk of moderate intensity exercise. Daily self-
reported commuting details were verified by GPS tracking. All subjects underwent 
assessment of body composition, resting blood pressure, glycemic control, and lipid 
profile at the beginning and end of the study. Data for final analyses were available in 
62 subjects. Commuting details indicated that the subjects randomized to IG changed 
their commuting habits. HbA1c decreased by 0.2% [95%CI: −0.3, −0.2] in IG-PT 
but was not statistically different between groups (P =  .06). LDL cholesterol de-
creased in IG-C by 0.8 mmol/L [−1.1, −0.4] and by 0.6 mmol/L [−1.2, 0.1] in IG-PT 
which can be considered biologically relevant but did not yield statistical signifi-
cance. Body composition and blood pressure did not differ between groups. Active 
commuting to work for 12  months did not change body composition but yielded 
relevant changes in lipid profile and glycemic control. Health benefits of active com-
muting should be addressed by healthcare professionals when counseling individuals 
that seek to improve their cardiovascular risk profile.
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people in developed countries (about 75%) does not meet this 
target.6 Considering the increasingly sedentary lifestyle,8 ac-
tive commuting by means of walking or cycling to and from 
work is a type of PA that can be integrated into everyday life.9 
However, active commuting to work has declined in high-in-
come countries in recent decades.10 Therefore, encouraging 
population-wide engagement in PA is a key priority for most 
stakeholders in healthcare systems to address the growing 
burden of CVD.
Active commuting has previously been associated with 
lower risk of CVD and all-cause mortality in popula-
tion-based observational studies.3,11,12 PA unfolds its CVD 
preventive effect via modulation of classic cardiovascular 
risk factors, including body mass-, blood pressure-, blood 
glucose-, and lipid-lowering effects. In a recent Danish 
study, 6  months of bike commuting to work for 5  d/wk 
improved peripheral insulin sensitivity and body compo-
sition in overweight or class 1 obese individuals.13 Using 
the same study design, in which exercise intensity recom-
mendations were monitored in addition to weekly contact 
between the investigators and participants, lipid profile did 
not improve.14
In the present prospective, randomized, and controlled 
study, we aimed to investigate whether achieving lifestyle 
changes by introducing active commuting to work verified 
by wearable GPS trackers, without exercise intensity require-
ments and thus resembling a real-world intervention, improve 
CVD risk factor profile and body composition over a time 
span of 12 months.
2 |  METHODS
2.1 | Study approval and registration
The data derived from participants of the GISMO 
(Geographical Information Support for Healthy Mobility) 
study. The study was performed in accordance with the 
Declaration of Helsinki and its current amendments and 
was approved by the Ethical Committee of the Paris Lodron 
University Salzburg, Austria (EK-GZ: 43/2016). The study 
was registered at ClinicalTrials.gov (NCT03098719).
2.2 | Subject recruiting
The recruiting was carried out within the local hospital, 
Salzburger Landeskliniken, with approximately 6500 
employees. In total, 655 possible participants were 
contacted via phone calls and 6392 E-mails were sent out 
with permission of the hospital directorate. A total of 300 
employees were initially interested in participating. Of these, 
223 were not invited for baseline assessment due to reasons 
such as already actively commuting, or known physical 
or psychological conditions, which would have made the 
conclusion of the study difficult. A more detailed description 
of the study design and the recruitment process is provided 
elsewhere.15,16
2.3 | Study population and 
group assignment
Seventy-three hospital employees with a predominantly pas-
sive way of commuting to work were randomly assigned into 
an intervention (IG) or a control group (CG) in a 2:1 fash-
ion. The IG was further divided into a public transportation/
active commuting (IG-PT) and cycling (IG-C) group, de-
pending on the subject's availability of cycling paths, public 
transportation, and personal preference. Both IG groups were 
prompted to reach the WHO recommendation of 150 min-
utes of moderate intensity PA per week during their commute 
for 12 months. The CG was asked not to change their pas-
sive mode of commuting. Detailed information about medi-
cal history and current medication are reported elsewhere.15 
All subjects provided written informed consent before study 
inclusion.
2.4 | Physical activity assessment
Each subject kept a diary to evaluate distances covered dur-
ing active commuting. Additionally, subjects were given a 
wearable device with an integrated GPS tracker and optical 
heart rate sensor (Polar M200, Polar Electro Oy, Finland) for 
two weeks at the beginning as well as at the end of the study, 
to validate diary entries.17
2.5 | Body composition and cardiovascular 
risk factor assessment
Data were collected at the beginning and the end of the 
study. Anthropometric data were obtained by measuring 
body mass, height, waist, and hip circumferences following 
standardized procedures.18 Body mass index (BMI) was 
calculated according to the formula of Keys.19 Sum of 
skinfold thicknesses was measured with Harpenden callipers 
using the four site skinfold measurement.20 Systolic and 
diastolic blood pressure (BP) was measured once at rest by 
the auscultatory method using an adequately sized upper 
arm cuff and a sphygmomanometer with the participant in 
a supine position. Venous blood samples were drawn after 
a 10  hours overnight fast. Fasting glucose, HbA1c, total 
cholesterol (CHOL), high-density lipoprotein cholesterol 
(HDL), and triglycerides (TRI) were analyzed in plasma by 
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enzymatic methods with a cobas 8000 (Roche Diagnostics). 
Low-density lipoprotein cholesterol (LDL) was calculated 
according the Friedewald Equation.21
2.6 | Cardiovascular risk scores
Two widely used cardiovascular risk scores were calculated 
for every subject: the Framingham Risk Score (FRS)22 and the 
HEART Score (HS) of the European Society of Cardiology 
(ESC).23 FRS estimates the 10-year risk of a subject to 
develop coronary heart disease, while HS was designed to 
estimate the 10-year risk of cardiovascular death. The FRS 
uses the following variables: age, male/female gender, total 
cholesterol, high-density lipoprotein (HDL) cholesterol, 
current smoking, and systolic blood pressure. The HS uses 
age, male/female gender, total cholesterol, current smoking, 
systolic blood pressure, and country.
2.7 | Statistical analyses
All variables were tested for normal distribution using 
the Kolmogorov-Smirnov test. Statistical comparison of 
T A B L E  1  Baseline characteristics of all participants, participants of control group (CG), public transportation plus active commuting group 
(IG-PT), and cycling group (IG-C)
All participants 
(N = 62) CG (N = 17) IG-PT (N = 23) IG-C (N = 22) P
Age, years 46 [44, 49] 45 [39, 50] 47 [43, 51] 47 [44, 51] .666
Men, % 36 29 30 45
Anthropometrics
Height (cm) 171 [169, 173] 171 [167, 174] 169 [165, 173] 174 [169, 178] .197
Body mass (kg) 76.5 [72.3, 80.7] 77.7 [67.3, 88.2] 73.5 [67.2, 79.8] 78.7 [71.9, 85.5] .542
BMI (kg/m2) 26.0 [24.9, 27.2] 26.4 [23.6, 29.3] 25.8 [23.9, 27.6] 26.0 [24.2, 27.7] .897
Waist circumference (mm) 91.1 [87.7, 94.4] 92.6 [84.2, 101.0] 89.1 [84.2, 94.1] 91.9 [86.4, 97.4] .672
Hip circumference (mm) 103.2 [100.3, 106.1] 101.8 [95.1, 108.6] 103.3 [97.9, 108.8] 104.1 [100.4, 107.8] .821
Waist/hip ratio 0.88 [0.86,0.90] 0.91 [0.86,0.96] 0.86 [0.84,0.89] 0.88 [0.84,0.92] .211
Skinfold (mm) 83.9 [74.7, 93.1] 88.9 [65.5, 112.3] 83.2 [68.0, 98.4] 80.8 [67.6, 94.0] .783
Blood pressure
RRsys (mm Hg) 114 [111, 117] 114 [107, 120] 112 [108, 117] 117 [110, 123] .488
RRdia (mm Hg) 72 [69, 75] 71 [66, 75] 71 [67, 75] 75 [69, 80] .406
Glucose metabolism
GLU (mg/dL) 78.0 [74.7, 81.3] 78.2 [71.3, 85.0] 75.3 [79.8, 75.3] 80.7 [74.0, 87.4] .387
HbA1c (%) 5.3 [5.3, 5.4] 5.4 [5.2, 5.5] 5.3 [5.3, 5.4] 5.4 [5.2, 5.5] .940
Lipid metabolism
TRI (mg/dL) 90.9 [79.9, 101.9] 86.0 [59.6, 112.5] 98.0 [80.4, 115.5] 87.2 [69.3, 105.2] .619
CHOL (mg/dL) 205.3 [196.6, 214.0] 200.2 [180.3, 220.0] 211.8 [196.3, 227.0] 202.4 [189.4, 215.4] .513
CHOL (mmol/L) 5.3 [5.1, 5.5] 5.2 [4.7, 5.7] 5.5 [5.1, 5.9] 5.2 [4.9, 5.6]
HDL (mg/dL) 74.3 [68.2, 80.3] 83.7 [65.9, 101.5] 68.4 [60.9, 75.9] 73.1 [65.3, 80.9] .127
HDL (mmol/L) 1.9 [1.8, 2.1] 2.2 [1.7, 2.6] 1.8 [1.6, 2.0] 1.9 [1.7, 2.1]
LDL (mg/dL) 113.4 [105.6, 121.2] 101.1 [89.9, 112.3] 123.9 [108.4, 139.4] 112.0 [100.0, 124.3] .062
LDL (mmol/L) 2.9 [2.7, 3.1] 2.6 [2.3, 2.9] 3.2 [2.8, 3.6] 2.9 [2.6, 3.2]
LDL/HDL ratio 1.7 [1.5, 1.9] 1.4 [1.1, 1.7] 2.0 [1.6, 2.4] 1.6 [1.4, 1.9] .050
Cardiovascular risc
FRS score 2.4 [1.6, 3.1] 3.1 [0.8, 5.3] 2.2 [1.1, 3.2] 2.1 [1.1, 3.0] .570
HS score 0.50 [0.33, 0.67] 0.57 [0.10, 1.04] 0.50 [0.20, 0.81] 0.46 [0.29, 0.63] .882
Note: Data are unadjusted mean [95% CI]. Statistics: one-way ANOVA.
Abbreviations: BMI, Body mass index; CHOL, Total cholesterol; Circ, Circumference; FRS score, Framingham Risk Score; GLU, fasting blood glucose; HbA1c, 
Hemoglobin A1c; HDL, HDL Cholesterol; HS score, HEART Score of the European Society of Cardiology (ESC); LDL, LDL Cholesterol; RRdia, diastolic blood 
pressure; RRsys, systolic blood pressure; Skinfold, Sum of 3-point skinfold thickness measured with the calliper method; TRI, Triglycerides.
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baseline values and distances covered during the commute 
to work between groups was performed by one-way 
ANOVA. Per-protocol comparison of outcome variables 
between groups was calculated by one-way ANCOVA using 
baseline values and gender as covariates and subsequent 
post hoc testing with Bonferroni correction. A two-way 
ANCOVA was performed to test whether the intervention 
was more effective in overweight individuals. Descriptive 
data are presented as unadjusted means and 95% confidence 
intervals (CI) or unadjusted means and 95% CIs of the deltas 
between beginning and end of the study. A P value of ≤.05 
(two-sided) was considered statistically significant. Cohen's 
d was calculated to estimate effect sizes. All statistical 
analyses were performed with IBM SPSS Statistics version 
24 (SPSS. Inc).
3 |  RESULTS
Overall, data for final analyses were available in 62 sub-
jects. Thereof, 21 were working as nurses, 9 as physicians, 
20 working in administration, and 12 practiced various other 
professions within the hospital. Baseline characteristics of 
all participants are presented in Table 1. Passive and active 
distances covered during participant's commute to work are 
presented in Table 2. Detailed baseline characteristics includ-
ing medication, adherence to the study protocol, and study 
dropouts are outlined elsewhere.15,16 Mobility data prove 
high compliance to the respective activity recommendations 
for CG and the two intervention groups.15
3.1 | Body composition
At baseline, 58% of subjects were overweight or obese (CG: 
53%; IG-PT: 57%; IG-C: 64%) as expected in a predominant 
sedentary study population. Changes in body composition 
variables did not differ between groups (Table  3). No 
significant dose-response relationship could be observed 
regarding body composition.24 In a subanalysis where both 
interventions (IG-PT and IG-C) were pooled, no statistically 
significant difference between overweight compared to 
normal body mass participants with regard to anthropometric, 
blood pressure, lipid, and glucose profile variables were 
observed (all P> .1).
3.2 | Blood pressure, lipid profile, and 
glycemic control
Changes in lipid profile, glycemic control and blood pres-
sure did not differ statistically significantly between groups 
(Table 3). However, LDL decreased in IG-C by 13% (−0.8 
[−1.1, −0.4]) and in IG-PT by 8% (−0.6 [−1.2, 0.1]; 
pGroups = 0.395). HbA1c decreased by 0.2% [95% CI: −0.3, 
−0.2] in IG-PT and by 0.1% [95% CI: −0.2, 0] in CG, but was 
not statistically different between groups (P = .06; Table 3). 
No significant physical activity dose-response relationship 
could be observed regarding HDL. 24
3.3 | Cardiovascular risk scores
Changes in FRS and HS scores did not differ significantly 
between groups (Table 3).
4 |  DISCUSSION
In the present study, active commuting to work for 12 months 
did not change body composition but yielded relevant 
changes in glycemic control and lipid profile.
HbA1c is the gold standard for monitoring glycemic con-
trol, and it has been shown that HbA1c levels starting with 
5.5% were associated with increased incidence of ischemic 
stroke, coronary heart disease, and all-cause death in non-di-
abetic individuals.25 Physical activity programs improve 
glycemic control among both diabetic and non-diabetic pop-
ulations,26 and exercise of more than 150minutes a week was 
associated with HbA1c reductions of 0.89%.27 In the pres-
ent study, the mean HbA1c was 5.3% at study entry and we 
observed a borderline significant difference in HbA1c be-
tween groups (P=.06) and improvement in IG-PT (−0.2%) 
compared to CG (P=.06). Considering that elevated HbA1c 
T A B L E  2  Passive and active distances covered during commute to work from control group (CG), public transportation plus active 
commuting group (IG-PT), and cycling group (IG-C)
Covered distances CG (N = 17) IG-PT (N = 23) IG-C (N = 22) P
Walking, km/year 110 [19, 202] 305 [203, 407] 65 [12, 119] <.001
Cycling, km/year 35 [0, 73] 450 [185, 716] 1673 [1159, 2187] <.001
Public transportation, km/
year
273 [0, 681] 1861 [357, 3366] 1248 [0, 2642] .230
Car, km/year 2371 [30, 4711] 299 [73, 526] 322 [29, 616] .016
Note: Data are unadjusted mean [95% CI]. Statistics: one-way ANOVA.
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levels of ≥5.5% results in an increased CVD risk,25 it is likely 
that the magnitude of improvement in glycemic control ob-
served in the present study might have lead to long-term ben-
efits regarding CVD health.
Current international recommendations suggest tailoring 
intervention strategies for the prevention of CVD based on 
total CVD risk.7 Considering the well-established, direct re-
lationship between dyslipidemia and CVD,28 interventions 
that improve lipid profiles are considered a main pillar in 
preventive cardiovascular medicine. 7 In a meta-analysis of 
studies involving 12 weeks or more of aerobic exercise, LDL 
fell by 5% and triglyceride levels fell by 3.7% whereas HDL 
cholesterol increased by 4.6%.29 In a study conducted by de 
Geus et al, 65 subjects were asked to cycle to work at least 
three times a week for 12 months and LDL decreased and 
HDL increased significantly in this group.30 In contrast, in 
a controlled study conducted by Gram et al overweight and 
obese subjects were asked to cycle to work for 6 months and 
no effects with regard to lipid profile was observed between 
groups.14 Our results are in line with the results of Gram 
et al, as we did not observe a statistically significant dif-
ference between groups. However, LDL decreased in IG-C 
by 13% (−0.8 mmol/L) and by 8% (-0.6 mmol/L) in IG-PT. 
Considering that long-term exposure to 1 mmol/L lower LDL 
has been associated with a 55% reduction in CVD risk,31 the 
CVD preventive effect of active commuting to work could 
be considered relevant in the present study. Regular exercise 
training has been repeatedly shown to result in an increase 
T A B L E  3  Changes in outcomes following 12 months of active commuting of all participants and participants of control group (CG), public 
transportation plus active commuting group (IG-PT), and cycling group (IG-C)
CG (N = 17) IG-PT (N = 23) IG-C (N = 22)
P (Effect 




Body mass (kg) 0.9 [−1.1, 2.8] −0.4 [−1.5, 0.7] 0.4 [−1.6, 2.4] .675 (0.014) .999 .999
BMI (kg/m2) 0.3 [−0.4, 1.0] −0.2 [−0.5, 0.2] 0.1 [−0.5, 0.8] .458 (0.027) .811 .999
Waist circumference 
(mm)
−0.3 [−2.0, 1.4] −1.6 [−2.9, −0.3] 0.5 [−1.9, 2.9] .105 (0.076) .955 .970
Hip circumference (mm) 1.5 [−1.6, 4.6] −1.3 [−2.8, 0.3] 0.1 [−1.7, 1.8] .162 (0.062) .174 .697
Waist/hip ratio 0 [−0.1, 0.0] 0 [0, 0] 0 [0, 0] .328 (0.038) .999 .999
Skinfold (mm) −8 [−19, 3] −9 [−14, −4] −3 [−10, 3] .343 (0.037) .999 .999
Blood pressure
RRsys (mm Hg) 3 [−3,9] 3 [−3, 9] 3 [−4,8] .861 (0.005) .999 .999
RRdia (mm Hg) 7 [3, 12] 7 [3, 10] 7 [2, 11] .971 (0.001) .999 .999
Glucose metabolism
GLU (mg/dL) 5.0 [−4.3, 14.3] 8.9 [2.2, 15.6] 5.7 [−2.0, 13.3] .678 (0.014) .999 .999
HbA1c (%) −0.1 [−0.2, 0] −0.2 [−0.3, −0.2] −0.2 [−0.2, −0.1] .058 (0.097) .060 .999
Lipid metabolism
TRI (mg/dL) 6.8 [−19.4, 33.0] 9.9 [−9, 28.7] −4.7 [23.9,14.5] .130 (0.069) .999 .688
CHOL (mg/dL) −8 [−20.8, 4.6] −8 [21.4, 5.4] −18.7 [−28.1, −9.2] .193 (0.056) .999 .762
CHOL (mmol/L) −0.5 [−1.2, 0.3] −0.5 [−1.2, 0.3] −1.1 [−1.6, 0.6] .193 (0.056)
HDL (mg/dL) −8.5 [−20.7, 3.6] −2.7 [7.0, 1.6] −4.4 [8.7, 0] .763 (0.009) .999 .688
HDL (mmol/L) −0.5 [−1.2, 0.3] −0.5 [−1.2, 0.3] −1.1 [−1.6, 0.6] .763 (0.009)
LDL (mg/dL) −1.5 [−10.5, 7.6] −10.3 [−21.9, 1.4] −13.3 [−21.2, −5.3] .395 (0.032) .999 .543
LDL (mmol/L) −0.1 [−0.6, 0.4] −0.6 [−1.2, 0.1] −0.8 [−1.1, −0.4] .395 (0.032)
LDL/HDL ratio 0.1 [−0.1, 0.3] −0.1 [−0.4,0.2] −0.1 [−0.3,0] .483 (0.025) .999 .766
Cardiovascular risc
FRS score −0.1 [−1.4, 1,3] 0.4 [−0.3, 1.0] −0.5 [−1.0, 0.1] .234 (0.050) .999 .810
HS score 0.0 [0,0] 0.0 [0,0] 0.0 [0,0] .342 (0.037) .507 .707
Note: Data are unadjusted mean (95% CI). Statistics: ANCOVA with baseline values and gender as covariates with post hoc pairwise comparison adjusted for multiple 
comparisons (Bonferroni correction).
Abbreviations: BMI, Body mass index; CHOL, Total cholesterol; Circ, Circumference; FRS score, Framingham Risk Score; GLU, Fasting blood glucose; HbA1c, 
Hemoglobin A1c; HDL, HDL Cholesterol; HS score, HEART Score of the European Society of Cardiology (ESC); LDL, LDL Cholesterol; RRdia, diastolic blood 
pressure; RRsys, systolic blood pressure; Skinfold, Sum of 3-point skinfold thickness measured with the calliper method; TRI, Triglycerides.
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in HDL and decrease in TRI. In the present study, such ef-
fects could not be documented, which might be due to the 
lower CVD risk in our study subjects and the absence of clear 
dietary recommendations. Also, no recommendations were 
given with regard to exercise intensity, which has previously 
been shown in the Copenhagen City Heart Study32 to have an 
impact on lipid profiles.
Previous population-based, long-term observational stud-
ies have reported that compared with car commuters, active 
commuters had lower baseline BMI and percentage body fat, 
and lower rates of hypertension.10,33-35 The present interven-
tional, randomized, and controlled study could not confirm 
these effects which is in line with the results of the study 
conducted by de Geus et al. 30 Differences in study design 
like selection bias in non-randomized studies may contrib-
ute to these inconsistent findings. In addition, in contrast to 
other studies demonstrating weight loss secondary to an ac-
tive commuting intervention,13,36 our study participants had 
lower BMI, and thus, weight loss and also other concomitant 
improvements are more challenging to achieve.
This study has some limitations. No a priori sample size 
calculation was performed since the sample size was defined 
by the willingness of includable hospital staff to participate 
in the study. However, great effort was undertaken to recruit 
as many participants as highlighted by the recruitment pro-
cess provided elsewhere.16 Exercise intensity during active 
commuting was not regularly monitored. Thus, insufficient 
exercise intensity during active commuting might have at-
tenuated our results. However, the lack of exercise intensity 
requirements better resembles a real-world intervention. 
Another limitation is that full nutrition information of study 
participants was not available. Finally, the study design did 
not include data about physical activity during leisure-time 
activities. In conclusion, the present study demonstrates that 
active commuting to work for 12  months does not change 
body composition but yields relevant changes in lipid mark-
ers and glycemic control. These changes have the potential to 
impact further prevention strategies such as the necessity of 
lipid-lowering or antidiabetic medication.
5 |  PERSPECTIVE
Previous, mainly observational, studies have reported that ac-
tive commuting has beneficial effects on body composition 
and most major CVD risk factors. Our results indicate that 
active commuting to work for 12 months improves glycemic 
control and lipid profile whereas other risk factors like body 
composition were not affected. Still, considering the magni-
tude of HbA1c and LDL reduction by active commuting in 
the present study, benefits of active commuting should be 
addressed by healthcare professionals when counseling indi-
viduals that seek to improve their cardiovascular risk profile.
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